Biopharma investors zero in on oncology and immunology

Biopharma investors are staying focused on the oncology and immunology sectors as major mergers fuel growth in those areas, according to an April 30 report from The Compass.

Changes in disease burden can influence mergers and acquisitions (M&A) activity in these sectors. The report found an increase in new patients associated with oncology providers in recent years. 

In March, Pfizer announced its intention to acquire cancer therapeutics company Seagen for $43 billion. The acquisition amount exceeds the prices of all of Pfizer’s acquisitions since 2019, according to the report.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars